Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 38
  • Journal CiteScore: 46.78
  • Journal Impact Factor: 1.95
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
  • ResearchGate
Share This Page

Case Report - (2022) Volume 14, Issue 10

Prevent Neurogenic Muscle Strength using Operational Ingredients

Sadhwy S*
 
Department of Pharmacology, Sweden
 
*Correspondence: Sadhwy S, Department of Pharmacology, Sweden, Email:

Received: 26-Sep-2022, Manuscript No. ijddr-22-13181; Editor assigned: 30-Sep-2022, Pre QC No. PQ-13181; Reviewed: 13-Oct-2022, QC No. ijddr-22-13181; Revised: 17-Oct-2022, Manuscript No. ijddr-22-13181; Published: 31-Oct-2022, DOI: 10.36648/0975-9344.14.10.983

Abstract

Debilitating neurogenic muscular atrophy is characterized by a diminished interaction between motor neurons and skeletal fibers and can be brought on by disease or aging-related neurotrauma.In situations where neuroperformance is declining, two current therapeutic approaches for preserving muscle mass are physical activity and pharmacotherapy.They slow the disease's progression but do not provide a specific remedy.Nutritional support can help lessen neuromuscular atrophy and is an important component of personalized medicine's success.Here, we summarize the sub-nuclear pathways set off by skeletal muscle denervation that may be impacted by functional enhancements.This narrative review examines and discusses studies on the use of functional ingredients to combat neuromuscular atrophy, focusing on their therapeutic or preventative effects on skeletal muscle.After considering the experimental models of rodent denervation and amyotrophic lateral sclerosis, as well as information gleaned from human studies and the use of experimental animal models, we propose an experimental model of denervation caused by aging.I scrutinized the model.

Keywords

Nutraceuticals; Natural Compounds; Muscle Wasting; Neurodegenerative Diseases; Sarcopenia; Aging

Introduction

Neurogenic muscle decay is a characteristic piece of maturing and happens at whatever point an infection or injury to the substantial sensory system happens.Diseases that only affect the motor neurons include Guillain-Barré syndrome, spinal muscular atrophy, and amyotrophic lateral sclerosis (ALS) [1]. On the other hand, poliomyelitis and multiple sclerosis are two additional diseases that have the potential to harm the peripheral nervous system.Denervation of muscle fibers is another important pathogenic mechanism in cancer cachexia syndrome-associated muscle wasting.Skeletal muscle undergoes remodeling when trophic innervation is lacking: The surrounding myofibers compress some of the myofibers, giving them an angular appearance, and myonuclei are moved to the center of the myofibers [2]. The disorganization of myofibrils and sarcomeres, the sarcotubular system, mitochondria, and nuclear localization are all directly correlated with the duration of ultrastructural denervation.If there isn't a significant increase in the number of macrophages and muscle stem cells, the surrounding tissues, in addition to the skeletal muscle, undergo remodeling. Two examples of these modifications are the progressive devascularization and activation of fibro-adipogenic progenitors (FAPs), which aid in the formation of fibro-fatty tissue. The effects of denervation on fast and slow fibers are distinct:In the rat EDL, the kinetics of myofiber atrophy have varied. Type II (fast) muscle fibers are first affected shortly after denervation, whereas type I (slow) muscle fibers resist atrophy for several months [3-5]. The histopathological changes brought about by denervated muscles have been broadly examined somewhere else.These processes may be reversible in physiological conditions like aging.

Skeletal Muscle Denervation-Induced Pathways

When skeletal muscle signaling pathways are activated and innervation is lost, neurogenic muscle atrophy occurs, leading to pathological responses and adaptations.Skeletal muscle fibers initiate three pathways for the degradation of proteins upon denervation:the Ca2+-activated cysteine proteases (calpains), the autophagic/lysosomal pathway, and the ubiquitin- proteasome system (UPS).In addition, high oxidative stress and redox imbalance have a strong correlation with neurogenic muscle atrophy, despite the fact that their final causal roles are debatable.Similar to this, it is still unclear whether neurogenic muscle atrophy is influenced by the activation of the AKT-mTOR signaling cascade following muscle denervation [6-9]. We will briefly discuss the primary signaling pathways that are activated when innervation in the skeletal muscle is lost, focusing on the atomic points that are likely to be altered by eating nutritious food varieties.

System of Ubiquitin-Proteaseases

A enzymatic reaction cascade is used to activate the UPS following the denervation of skeletal muscle.This causes a chain of ubiquitin molecules to be covalently attached to the proteins that the 26S proteasome will degrade.There are three broad categories of enzymes that are responsible for ubiquitination, tagging, and transporting proteins to the proteasome for degradation:the conjugating enzyme E2, the activating enzyme E1, and the ubiquitin-protein ligase E3. The E3-ubiquitin ligases are essential to this proteolytic cascade because they bind the ubiquitin chain specifically to a specific protein target [10].

Muscle RING Finger-1 (MuRF1), the newly discovered MUSA1 and SMART1, are collectively referred to as "atrogenes" because they participate in the proteasome-mediated breakdown of muscle protein and have a disposition that grows in response to various atrophic increases.Muscle decay F-Box (MAFbx) and Muscle RING Finger-1 (MuRF1) are two muscle-explicit E3 ubiquitin ligases.When their demeanor is quiet or diminished, the skeleton's muscle is protected from degeneration caused by denervation.Innervation loss influences the expression of E3-ubiquitin ligase, which in turn affects a number of kinases, including the p38 mitogen-activated protein kinases (MAPKs) and protein kinase B (AKT) that control the activity of the Forkhead box O (FoxO) transcription factors.Atrogene transcription is also influenced by inflammatory cytokines like TNF, TNF-like weak inducer of apoptosis (TWEAK), NF-kB, Stat3, and FoxO. Particularly, denervation encourages fibrosis and muscle wasting by causing FAPs to persistently activate Stat3 and secrete IL6. Reliable denervation also alters calcium influx by activating the Class II HDACs-myogenin axis in a mouse model of ALS.This causes transcription to become active in the MuRF1 and atrogin-1 genes.

Autophagy

By engulfing cytosolic material into double-membraned vesicles (autophagosomes) and assisting them in fusing with lysosomes for degradation, autophagy, also known as macroautophagy, is a highly conserved proteolytic pathway that coordinates the clearance of damaged proteins and organelles.Macroautophagy is the term used to describe this process.The Atg family of proteins are in charge of the main autophagy steps:from vesicle nucleation through vesicle extension (phagophore arrangement) and closure (autophagosome development), as well as the autophagosome-lysosome combination that forms the autolysosome and its fragmentation.Autophagy is always active in all cells to support stress resistance, remove damaged organelles, and generate energy.Instead, autophagy imbalances affect skeletal muscle

homeostasis:Muscle hyperactivation is the cause of muscle wasting in many diseases, while impaired autophagy is the cause of myopathy-related diseases and muscle degeneration.

The unc-51-like kinase 1 (Ulk1)/Atg1 complex, which recruits Atg proteins to the autophagosome formation site to initiate autophagosome formation, is essential for both autophagosome assembly and autophagy flux maintenance.The upstream complex's activity is directly controlled by AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR).Ulk1 is, in fact, activated by activated AMPK, and mTOR complex 1 (mTORC1) inhibits it when nutrients are available.

Innervation loss is responsible for Ulk1 upregulation, which also increases autophagy flux by increasing the expression of other Atg genes like LC3, Atg7, p62, and Beclin1 through AKT- and FoxO3-dependent mechanisms. On the other hand, other authors claim that denervation decreases autophagic flux in skeletal muscle through increased mTORC1 activity.It is interesting that some players, like FoxO3 and the E3-ubiquitin ligase Trim32, coordinately activate both the UPS and the autophagic response when the cell is denervated.

Autophagy does not, in and of itself, induce neurogenic muscle atrophy in the majority of published studies, regardless of the pathway that is involved, despite the fact that it appears to play a role when muscle atrophy is induced in response to denervation concurrently with the activation of the TGFb/HMGB1 pathway. Various experimental settings, such as the examination of various muscles and/or distinct time points following denervation, may help resolve these contradictory conclusions.

Dietary Fiber, Probiotics, and Prebiotics

In addition to aging, skeletal muscle wasting conditions are linked to changes in the gut biota and have a significant impact on the intestinal mucosa.On the other hand, by changing energy digestion, insulin awareness, and fundamental aggravation and resistance, the stomach microbiota may can possibly impact skeletal bulk.The importance of gut microbiota for maintaining skeletal muscle homeostasis and physiology has recently been demonstrated by comparing pathogen-free and germ-free mice. The pathogen-free mice's gut microbiota were transplanted to reverse the skeletal muscle atrophy and clear molecular signs of muscle denervation in the first group.When pathogen-free mice's gut microbiota are transplanted into germ-free mice, both slow and fast muscles are affected.Atrogin-1 and MuRF1, which are markers of skeletal muscle atrophy, decrease, and mitochondriogenesis and oxidative metabolism increase, restoring skeletal muscle mass.The gut microbiota and muscle mass are linked, either directly or indirectly, according to new research.Despite the fact that the prebiotics' and probiotics' mechanisms for saving muscle mass are not yet well understood, the gut microbiota may potentially influence muscles through endocrine and insulin sensitivity, energy metabolism, immunity, and inflammation.The microbiota composition can be altered through diet by increasing prebiotics, which are fermented non-digestible carbohydrates that stimulate the growth and/or activity(ies) of bacteria, or probiotics, which are live microorganisms that benefit the host's health.Prebiotics much of the time have pleiotropic impacts, influencing both fat tissue and lean mass while additionally managing digestion.

Altering the microbiota in the gut through diet may be a good way to treat elderly patients.In fact, feeding adult subjects dietary fiber increases glucose metabolism, muscle function, and lean body mass to rapidly and consistently alter the microbiome's composition, which includes all of the microbiota's genetic material and living members.The gut microbiota, for example, produce more short-chain fatty acids when there is a lot of fiber in the diet.Skeletal muscle mass, metabolism, and function are all regulated by these short-chain fatty acids in a crucial manner. Because it reduces insulin resistance, taking fiber supplements has also been shown to benefit metabolic disease patients. Sarcopenia is brought on by two mechanisms that are directly related to the concentration of pro-inflammatory cytokines.The administration of a prebiotic that was made up of a mixture of inulin and fructooligosaccharides for 13 weeks in an randomized, controlled, and double-blind study involving elderly people resulted in an increase in some functional parameters of skeletal muscle, consistent with the strategy of affecting the microbiota.

Calpains

Calpains play a role in the early stages of sarcomeric protein depolymerization, the subsequent debasement, and the neuromuscular intersection adjustment in atrophic conditions like muscle denervation.Desmin filament disassembly plays a direct role in neurogenic muscle atrophy, as calpain-1 downregulation prevents desmin loss, myofibril destruction, and muscle.The fact that desmin filaments must first be ubiquitinated by Trim32 before they can be disassembled by calpain-1 further demonstrates the intriguing synergy between the three proteolytic pathways triggered by denervation in skeletal muscle. In addition to calpains, calpastatins, their specific endogenous inhibitors, are altered in skeletal muscle upon denervation and as we get older.Overexpressing calpastatin prolongs the lifespan of rodents by preventing myofibroillar degradation and sarcopenia caused by calpains' autolytic protease activities in aged muscles.Calpastatin overexpression inhibits the autolytic protease activities of calpains, whereas atrophying muscles have a high calpain/calpastatin ratio, resulting in increased calpain proteolytic activity and loss of muscle mass.

Conclusions

A pharmaceutical intervention, exercise, and individualized dietary intervention could all be routinely administered as a therapeutic strategy to lessen the effects of neurogenic muscle atrophy.A method of this safety ought to be taken into consideration as well in order to slow down the age-related muscle wasting that occurs in sarcopenia.Preclinical research, particularly those involving animal models of muscle denervation, can provide a better understanding of the molecular mechanisms that underlie the functional food-mediated rescue of neurogenic muscle atrophy.The chance of miRNAs assuming a part in intervening the impacts of food on bulk as novel candidates.open the way to another field of study.More research on functional nutrients is needed to help develop strategies for precision medicine.

References

  1. Gao X, Ma Y, Sun L, Chen D, Mei C (2014) Cyclosporine A for the treatment of refractory nephrotic syndrome with renal dysfunction.Experimental and Therapeutic Medicine 7(2): 447-450.
  2. Indexed at, Google Scholar , Crossref

  3. , https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000297.pub2/abstract
  4. , https://www.sciencedirect.com/science/article/abs/pii/S0270929503700266
  5. Dai Y, Iwanaga K, Lin Y S (2004) In vitro metabolism of cyclosporine a by human kidney CYP3A5.Biochemical Pharmacology68(9): 1889-1902.
  6. Indexed at, Google Scholar , Crossref

  7. Benigni, Gagliardini, Tomasoni, Abbate, Ruggenenti (2004) Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 65: 2193-2200.
  8. Indexed at, Google Scholar , Crossref

  9. Benigni, Perico, Macconi (2016) Mitochondrial dynamics is linked to longevity and protects from end-organ injury: the emerging role of sirtuin 3. Antioxidants Redox Signal 25:  185-199.
  10. Indexed at, Google Scholar , Crossref

  11. Bernstein, Shen, Gonzalez Villalobos, Billet, Okwan Duodu (2011) Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr Opin Pharmacol 11: 105-111.
  12. Indexed at, Google Scholar , Crossref

  13. Bessho, Takiyama,   Kitsunai, Takeda, Sakagami (2019) Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci Rep 9: 147-154.
  14. Indexed at, Google Scholar , Crossref

  15. Bossi, Bernardi, De Nardo, Bramante, Candido (2016) Angiotensin 1-7 significantly reduces diabetes-induced leukocyte recruitment both in vivo and in vitro. Atherosclerosis 244:  121-130.
  16. Indexed at, Google Scholar , Crossref

  17. Brent, G A (2012) Mechanisms of thyroid hormone action. J Clin Invest 122: 3035-3043.
  18. Indexed at, Google Scholar , Crossref

Citation: Sadhwy S (2022) Prevent Neurogenic Muscle Strength Using Operational Ingredients. Int J Drug Dev Res J, Vol.14 No. 10: 983.